Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 7/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15275360 | 0.83 | EGFR (0.56) | LMNASMN1; SMN2MMP13NR1H4EGFR | |
| SCHEMBL14124971 | 0.81 | EGFR (0.60) | MMP13SLC22A8NR1H4EGFREPHX2 | |
| SCHEMBL16748804 | 0.73 | NR1H4 (0.46) | LMNASMN1; SMN2NR1H4PTGER4PTGER2 | |
| SCHEMBL13693078 | 0.71 | ALDH1A1 (0.59) | — | |
| SCHEMBL9915434 | 0.71 | NR1H4 (0.44) | LMNASMN1; SMN2MMP13NR1H4PTGER4 | |
| SCHEMBL27904058 | 0.71 | KMT2A (0.55) | LMNASMN1; SMN2 | |
| SCHEMBL9915408 | 0.70 | EGLN1 (0.45) | LMNA | |
| SCHEMBL13693158 | 0.69 | SMPD1 (0.68) | — | |
| SCHEMBL10782030 | 0.69 | ALDH1A1 (0.63) | — | |
| SCHEMBL9915360 | 0.67 | KDM4E (0.47) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2646436-B1 | MONOBACTAMS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | LMNA 4489/4885SMN1; SMN2 4574/4885MMP13 2794/4885 |
| US-20150148326-A1 | Monobactams | MGAM, MGAM2, BPGM | LMNA 4489/4885SMN1; SMN2 4574/4885MMP13 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.